- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Relevium Improves Financial Position and Provides Updates on Warrants Exercises
Advanced Proteome Therapeutics (TSXV:APC) is pleased to announce that the Japanese Patent Office has decided to grant a patent for APC’s Japanese Patent Application No. :2015-511804, titled “Site specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”. As quoted in the press release: “We are excited to announce the Japanese Patent Office …
Advanced Proteome Therapeutics (TSXV:APC) is pleased to announce that the Japanese Patent Office has decided to grant a patent for APC’s Japanese Patent Application No. :2015-511804, titled “Site specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”.
As quoted in the press release:
“We are excited to announce the Japanese Patent Office has granted us this patent,” commented Randal Chase, CEO of Advanced Proteome Therapeutics. “This patent represents additional opportunities beyond just the North American market for advancing our relationships with the global biotech and pharmaceutical communities.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.